[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 324,087
  • Shares Outstanding, K 249,298
  • Annual Sales, $ 14,560 K
  • Annual Income, $ -63,530 K
  • EBIT $ -23 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.60
  • Price/Sales 22.61
  • Price/Cash Flow N/A
  • Price/Book 6.24

Options Overview Details

View History
  • Implied Volatility 173.85% (+4.60%)
  • Historical Volatility 55.07%
  • IV Percentile 55%
  • IV Rank 21.62%
  • IV High 516.69% on 06/12/25
  • IV Low 79.27% on 04/21/26
  • Expected Move (DTE 25) 0.2890 (22.23%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 19
  • Volume Avg (30-Day) 406
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 13,264
  • Open Int (30-Day) 11,365
  • Expected Range 1.0110 to 1.5890

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 2
  • High Estimate $-0.02
  • Low Estimate $-0.03
  • Prior Year $-0.01
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +8.33%
on 05/20/26
1.6600 -21.69%
on 04/28/26
-0.3300 (-20.25%)
since 04/22/26
3-Month
1.2000 +8.33%
on 05/20/26
1.9850 -34.51%
on 03/02/26
-0.5100 (-28.18%)
since 02/20/26
52-Week
0.6000 +116.67%
on 05/23/25
2.0900 -37.80%
on 11/03/25
+0.6955 (+115.05%)
since 05/22/25

Most Recent Stories

More News
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.2372 (-1.29%)
BIOA : 16.61 (-0.78%)
LCTX : 1.3000 (-1.52%)
GERN : 1.2800 (+1.59%)
FATE : 2.25 (+7.14%)
Lineage Cell Therapeutics Q1 Earnings Call Highlights

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in...

LCTX : 1.3000 (-1.52%)
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial...

LCTX : 1.3000 (-1.52%)
Lineage Cell Therapeutics Reports Tomorrow With OpRegen Trial Data Still Undefined

Barchart Research What to Expect from LCTX Earnings LCTX Generated May 11, 2026 Current Price $1.3100 EPS Estimate $$-0.02 Consensus Rating Strong Buy Average Move 2.07% Lineage Cell Therapeutics Reports...

LCTX : 1.3000 (-1.52%)
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today...

LCTX : 1.3000 (-1.52%)
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site ...

LCTX : 1.3000 (-1.52%)
Lineage Announces Formation of Scientific Advisory Board

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.3000 (-1.52%)
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD)...

LCTX : 1.3000 (-1.52%)
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ...

LCTX : 1.3000 (-1.52%)
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.3000 (-1.52%)

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 1.4350
2nd Resistance Point 1.4000
1st Resistance Point 1.3500
Last Price 1.3000
1st Support Level 1.2650
2nd Support Level 1.2300
3rd Support Level 1.1800

See More

52-Week High 2.0900
Fibonacci 61.8% 1.5208
Fibonacci 50% 1.3450
Last Price 1.3000
Fibonacci 38.2% 1.1692
52-Week Low 0.6000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.